Enhancement of intranasal vaccination-improved immune protection and cost-effictiveness by combining optimised mucosal adjuvant and nasal delivery system (NASAL VACCINATION)

Project Information

NASAL VACCINATION

Grant agreement ID: QLK2-CT-2002-71587

Project closed

Start date 1 December 2002

End date 31 August 2005

Funded under

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Total cost € 1 679 650,00

EU contribution € 839 825,00

Coordinated by

EUROCINE AB
Sweden

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Call for proposal

Data not available

Funding Scheme

CRS - Cooperative research contracts

Coordinator

EUROCINE AB

• EU contribution: No data
• Address: Karolinska Institute Science Park, Foqdevreten 2 ; 171 77 STOCKHOLM ; Sweden
• Total cost: No data

Participants (6)

DIABACT AB

Sweden

• EU contribution: No data
• Address: Kungsgatan, 109 ; 751 05 UPPSALA
• Total cost: No data

FEM DESIGN AS

Norway

• EU contribution: No data
• Address: Sagveien, 21 ; 0459 OSLO
• Total cost: No data

FOUNDATION FOR TECHNICAL AND INDUSTRIAL RESEARCH AT THE NORWEGIAN INSTITUTE OF TECHNOLOGY

Norway

• EU contribution: No data
• Address: 1 D,Strindveien 4 ; 7465 TRONDHEIM
• Total cost: No data

OPTINOSE AS

Norway

• EU contribution: No data
• Address: Lokka Skogen 18c ; 0773 OSLO
• Total cost: No data

SIUMSURGERY AS

Norway

• EU contribution: No data
• Address: Sognsveien, 75 B ; 0865 OSLO
• Total cost: No data

SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL

Sweden

• EU contribution: No data
• Address: 2,Nobels vaag 18 ; 171 82 SOLNA
• Total cost: No data